daily for 9 months. RT after androgen max (median 4.7mo) Solberg Biopsy at Locally Residual Use of 2011 of 45 months cancer in 66% adjuvant Widmark follow-up. (n=41) ADT 2009 Assessed endocrine only appears to 3/12 for 1 patients and have year then cancer. 22% (12) 6/12 ADT+RT death or patients; decreased Feb 2008. p<0.0001. rate of residual cancer in an population. Stone N/A 2 years. 30 (10%) had Again 2000 (dose Assessed cancer post implant (n=296) every 6/12 (note biopsies. 4 the role 3 and at 2 not were positive of ADT in months years after specific in who reducing before implant. received and after hormone brachy blockade, positive implant. while 26 were biopsy. positive in Link to those who had clinical 750mg not (p=0.002) outcomes. daily 3 Only months benefited before high-risk in and after sub implant. analysis. + brachy implant. Stone N/A 4 years. Prostate 1999 (dose Assessed 3 volume, the (n=145) and 6 freedom from reduction 3 months PSA-defined in prostate months and 6 cancer. failure. volume before month achieved. Mean PV and after intervals What reduction 35% brachy thereafter. proportion (R2-62). implant. Biopsy at 2 due to ADT actuarial years. or RT freedom from unknown. 750mg PSA failure daily 3
daily for 9 months. RT after androgen max (median 4.7mo) Solberg 2011 of Widmark 2009 Biopsy at 45 months follow-up. Assessed 3/12 for 1 year then 6/12 death or Feb 2008. Locally cancer. Residual cancer in 66% (n=41) endocrine only patients and 22% (12) ADT+RT patients; p<0.0001. Use of adjuvant ADT appears to have decreased rate of residual cancer in an population. Stone 2000 (n=296) (dose 3 months before and after brachy implant. 750mg daily 3 months before and after implant. + brachy implant. N/A 2 years. Assessed every 6/12 and at 2 years after implant. cancer (note not specific 30 (10%) had post implant biopsies. 4 were positive in who received hormone blockade, while 26 were positive in those who had not (p=0.002) Again the role of ADT in reducing positive biopsy. Link to clinical outcomes. Only benefited high-risk in sub analysis. Stone 1999 (n=145) (dose 3 months before and after brachy implant. 750mg daily 3 N/A 4 years. Assessed 3 and 6 months and 6 month intervals thereafter. Biopsy at 2 years. cancer. Prostate volume, freedom from PSA-defined failure. Mean PV reduction 35% (R2-62). actuarial freedom from PSA failure the reduction in prostate volume achieved. What proportion due to ADT or RT unknown.
auspar-leuprorelin-180905.docx